Skip to main content

Table 1 Effect size of ratio of MΦ subsets in total SF MΦs with patient reported outcome measures (PROMs)

From: Synovial fluid monocyte/macrophage subsets and their correlation to patient-reported outcomes in osteoarthritic patients: a cohort study

  CD14+CD16neg-MΦs/total SF MΦs (%) CD14+CD16+-MΦs/total SF MΦs (%) CD14lowCD16+-MΦs/total SF MΦs (%)
β (95% CI), adjusted p β (95% CI), adjusted p β (95% CI), adjusted p
Overall
 mean KOOS 0.379 (0.179, 0.610), p = 0.006 −0.376 (− 0.642, − 0.132), p = 0.025 −0.761 (− 1.601, − 0.030), p = 0.115
 mean KOOSa 0.380 (0.193, 0.613), p = 0.003 − 0.415 (− 0.682, − 0.178), p = 0.005 −0.545 (− 1.191, 0.048), p = 0.247
 mean WOMAC 0.431 (0.191, 0.710), p = 0.010 −0.459 (− 0.769, − 0.170), p = 0.018 −0.734 (− 1.738, 0.059), p = 0.224
 mean WOMACa 0.380 (0.193, 0.613), p = 0.003 −0.473 (− 0.800, − 0.159), p = 0.023 −0.500 (− 1.335, 0.138), p = 0.463
KOOS
 SYMPTOMS 0.187 (−0.055, 0.453), p = 0.459 −0.177 (− 0.491, 0.114), p = 0.667 −0.372 (− 1.227, 0.479), p = 0.869
 SYMPTOMSa 0.188 (− 0.040, 0.471), p = 0.437 − 0.228 (− 0.539, 0.045), p = 0.389 −0.153 (− 0.904, 0.573), p = 0.988
 PAIN 0.299 (0.066, 0.556), p = 0.069 −0.295 (− 0.594, 0.013), p = 0.215 −0.633 (− 1.526, 0.069), p = 0.271
 PAINa 0.288 (0.023, 0.579), p = 0.156 −0.308 (− 0.642, 0.016), p = 0.244 −0.450 (− 1.195, 0.202), p = 0.554
 ADL 0.477 (0.202, 0.796), p = 0.013 −0.458 (− 0.816, − 0.117), p = 0.054 − 1.094 (− 2.214, − 0.169), p = 0.052
 ADLa 0.482 (0.201, 0.797), p = 0.010 −0.492 (− 0.845, − 0.137), p = 0.038 −0.861 (− 1.788, − 0.127), p = 0.092
 QOL 0.431 (0.170, 0.702), p = 0.010 − 0.497 (− 0.792, − 0.215), p = 0.008 −0.463 (− 1.508, 0.432), p = 0.813
 QOLa 0.453 (0.253, 0.667), p = 0.002 −0.571 (− 0.826, − 0.357), q < 0.001 −0.231 (− 0.954, 0.459), p = 0.932
 SPORTS 0.502 (0.223, 0.869), p = 0.009 −0.454 (− 0.901, − 0.101), p = 0.104 −1.244 (− 2.164, − 0.512), p = 0.005
 SPORTSa 0.491 (0.213, 0.865), p = 0.014 −0.475 (− 0.925, − 0.122), p = 0.071 −1.033 (− 1.839, − 0.347), p = 0.031
WOMAC
 PAIN 0.322 (0.084, 0.608), p = 0.059 −0.327 (− 0.659, − 0.035), p = 0.137 −0.655 (− 1.616, 0.116), p = 0.330
 PAINa 0.312 (0.040, 0.616), p = 0.122 −0.347 (− 0.711, − 0.016), p = 0.167 −0.378 (− 1.203, 0.318), p = 0.753
 FUNCTION 0.477 (0.202, 0.795), p = 0.013 −0.458 (− 0.816, − 0.117), p = 0.054 −1.093 (− 2.213, − 0.168), p = 0.053
 FUNCTIONa 0.482 (0.201, 0.797), p = 0.010 −0.492 (− 0.845, − 0.137), p = 0.037 −0.860 (− 1.788, − 0.127), p = 0.092
 STIFFNESS 0.479 (0.194, 0.788), p = 0.010 − 0.592 (− 0.922, − 0.274), p = 0.007 −0.454 (− 1.517, 0.413), p = 0.815
 STIFFNESSa 0.453 (0.159, 0.777), p = 0.019 −0.580 (− 0.924, − 0.247), p = 0.010 −0.262 (− 1.217, 0.450), p = 0.951
  1. All correlations adjusted for sex, body mass index and age; N = 83. Values in boldface show results with significant effect estimates (β)
  2. monocytes/macrophages, SF synovial fluid, SFLs synovial fluid leukocytes, KOOS Knee Injury and Osteoarthritis Injury Score, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index, ADL activities of daily living, QOL quality of life
  3. aAdditionally adjusted for osteoarthritis state (i.e. early, Kellgren–Lawrence (KL) grade I/II, n = 24 or late, KL grade III/IV, n = 52); N = 76